Solventum Stock: Analyst Estimates & Ratings

Core Insights - Solventum Corporation (SOLV) is a healthcare company with a market cap of $12.8 billion, focusing on solutions in separation and purification, health information, medical solutions, medical device components, and oral care [1] Performance Overview - Over the past year, SOLV shares have gained 4.4%, underperforming the S&P 500 Index, which increased by nearly 14.5% [2] - Year-to-date (YTD) performance shows SOLV stock up 11.8%, while the S&P 500 has risen 16.5% [2] - Compared to the SPDR S&P Health Care Equipment ETF (XHE), which declined about 9.2% over the past year, SOLV's low double-digit returns on a YTD basis outshine the ETF's 5.1% losses [3] Financial Results - In Q3, SOLV reported an adjusted EPS of $1.50, exceeding Wall Street expectations of $1.43, and revenue of $2.10 billion, beating forecasts of $2.09 billion [4] - The company expects full-year adjusted EPS to be in the range of $5.98 to $6.08 [4] Analyst Expectations - For the current fiscal year ending in December, analysts expect SOLV's EPS to decline by 9.9% to $6.04 on a diluted basis [5] - SOLV has a strong earnings surprise history, beating consensus estimates in each of the last four quarters [5] - Among 15 analysts covering SOLV, the consensus rating is a "Moderate Buy," with five "Strong Buy" ratings, nine "Holds," and one "Strong Sell" [5] Recent Analyst Actions - The analyst configuration has become more bullish, with four analysts now suggesting a "Strong Buy" [6] - UBS maintained a "Neutral" rating on SOLV and raised the price target to $79, indicating a potential upside of 7% from current levels [6]